|

JAB 21822 Clinical Trials

4 actively recruiting trials

Also known as: Glecirasib

Pipeline

Phase 2: 1Phase 3: 1Phase 1/2: 2

Top Sponsors

  • Allist Pharmaceuticals, Inc.4

Indications

  • Cancer4
  • Lung Cancer3
  • KRAS P.G12C2
  • Non Small Cell Lung Cancer2
  • Pancreatic Ductal Carcinoma1

Other4 trials

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Phase 2
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Phase 1/2
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Phase 3
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.